Faramarzi E, Aftabi Y, Ansarin K, Somi MH, Gilani N, Seyedrezazadeh E. Polymorphism (-499C/G) in
DDAH2 promoter may act as a protective factor for metabolic syndrome: A case-control study in Azar-Cohort population.
ARCHIVES OF ENDOCRINOLOGY AND METABOLISM 2021;
65:443-449. [PMID:
34283907 PMCID:
PMC10522192 DOI:
10.20945/2359-3997000000391]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/07/2020] [Accepted: 03/14/2021] [Indexed: 11/23/2022]
Abstract
OBJECTIVE
Globally developing metabolic syndrome (MetS) prevalence as a major health problem can be related to multiple factors of genetic and environmental. Dimethylaminohydrolase 2 (DDAH2) is the main enzyme implicated in the cardiovascular system, which regulates the nitric oxide pathway. This study investigated the association of DDAH2 polymorphism -499C/G (rs805305) with the risk of MetS among the Azar-Cohort population.
METHODS
The occurrence of SNP rs805305 in the DDAH2 gene was tested using the PCR-RFLP method in 332 MetS cases and 294 healthy controls. Afterward, the association of the allele and genotypes with the risk of MetS and its components were examined.
RESULTS
The G allele and GC genotype were significantly associated with a reduced risk of MetS (P ≤ 0.001). Also, the dominant genetic model (GG+GC) significantly decreased the risk of MetS (P = 0.001), however, in sex subtypes MetS risk was significantly reduced in males before and in females after adjustment for age (P ≤ 0.02).
CONCLUSION
The -499C/G polymorphism of DDAH2 may play a protective role and reduce MetS risk among the Azar-Cohort population.
Collapse